Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy
Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy
pharmaceutical investing Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States
NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
